Odyssey Therapeutics, Inc. — Q3 2026 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2026. Odyssey is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases. It has no approved products and has not generated product-sales revenue. Amounts below are in U.S. dollars; financial statement amounts are converted from thousands to millions where appropriate.
Financial performance and position
- Revenue: No collaboration revenue in Q3 or the first nine months of 2026, versus $0.1 million and $3.0 million, respectively, in the comparable 2025 periods. The Pfizer and J&J collaboration obligations were completed in 2025.
- Expenses and losses: Q3 operating expenses were $56.7 million and net loss was $53.1 million, compared with $38.4 million and $35.5 million in Q3 2025. For the first nine months, operating expenses were $151.9 million and net loss was $144.1 million, versus $122.3 million and $115.1 million a year earlier. No meaningful product margin comparison is available because there are no product sales.
- Expense drivers: Nine-month R&D expense rose 16% to $110.7 million, chiefly from CRO and other external preclinical/clinical costs, including OD-001 trial activity. G&A fell to $29.1 million from $31.3 million, primarily due to lower professional fees and facility costs, partly offset by increased payroll and stock-based compensation.
- Fair-value item: Contingent consideration generated $12.1 million of expense in the first nine months of 2026, versus $4.3 million of income in 2025; Q3 expense was $3.3 million. Management attributed the increase principally to updated Rahko valuation assumptions after the IPO and the company’s increased market capitalization.
- Cash flow: Net cash used in operating activities was $117.1 million for the first nine months, compared with $104.1 million in 2025. Investing activities used $133.4 million, largely reflecting purchases of marketable securities net of maturities. Financing activities provided $289.5 million, primarily from the IPO and concurrent private placement.
- Liquidity: At September 30, cash and cash equivalents were $80.6 million and marketable securities were $306.3 million, totaling approximately $387.0 million. Current assets were $337.8 million versus current liabilities of $26.1 million. Accumulated deficit was $712.2 million; stockholders’ equity was $375.8 million.
- Debt and obligations: The filing does not report conventional borrowings. Lease liabilities totaled approximately $23.5 million on the balance sheet; future non-cancellable lease obligations were $27.7 million for operating leases and $0.6 million for finance leases. The company also reported $18.3 million of contingent consideration liabilities.
- Shares: 47,940,608 common shares were outstanding at September 30, 2026; 48,067,877 were reported outstanding as of November 2, 2026. Q3 basic and diluted net loss per share was $1.10, versus $7.78 in 2025; comparisons are affected by the IPO, share-count changes and reverse stock split.
Material changes and business developments
- Odyssey completed its IPO in May 2026, selling shares at $18.00 per share and reporting approximately $288.2 million of combined net proceeds from the IPO, concurrent private placement and underwriters’ option exercise. Preferred stock converted to common stock at the IPO.
- On May 1, 2026, the company effected a 1-for-9.7170 reverse stock split; share and per-share data were retroactively adjusted.
- OD-001, an oral RIPK2 inhibitor for ulcerative colitis, has completed induction treatment in a Phase 2a trial, and the company says it has achieved clinical proof-of-concept. Management plans a Phase 2b monotherapy trial and a Phase 2a combination trial; the filing’s risk discussion says topline results are expected in the second half of 2027.
- OD-002, an oral SLC15A4 inhibitor, has completed IND-enabling studies; the company expects to advance it into clinical development. Other programs remain preclinical or at discovery stage.
Outlook, risks and contingencies
- Management’s operating-plan estimate is that existing cash, cash equivalents and investments will fund operations into the second half of 2028. The filing cautions that the estimate depends on assumptions that may prove incorrect and that additional financing will be needed. A separate note says resources are expected to fund operations for at least 12 months from issuance; investors should reconcile the statements and their underlying assumptions.
- The company expects substantial losses and increasing expenses as it advances candidates, conducts trials, expands research and manufacturing activities, and bears public-company costs. Profitability depends on successful development, regulatory approval and commercialization; it may never be achieved.
- Key risks include clinical and regulatory failure or delay, patient enrollment, reliance on CROs and third-party manufacturers, competition, intellectual-property protection, financing and dilution, and geopolitical or macroeconomic disruption. The company conducts or relies on activities and vendors internationally, including in Ukraine and China.
- Rahko contingent consideration may reach $30 million if specified market-capitalization or exit-event conditions are met; no qualifying event had occurred as of September 30. IFM consideration may reach $30 million for each of the NLRP1 and MDA5 programs; no milestones were achieved or deemed probable at period-end.
- The company reported no material legal proceedings. Management concluded disclosure controls and procedures were effective at quarter-end and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Reconcile the cash runway disclosures—“second half of 2028” in MD&A versus at least 12 months from issuance in the financial-statement note—and assess the assumptions behind the forecast.
- Track OD-001 trial enrollment, design, combination-agent availability and the stated second-half 2027 topline-results timing; confirm whether subsequent updates alter the plan.
- Monitor quarterly operating cash burn, R&D commitments and financing needs against the approximately $387.0 million liquidity balance.
- Review changes in Rahko and IFM contingent consideration valuations, payment triggers and potential cash consequences.
- Assess dilution from outstanding options, equity plans and any future financing; confirm the post-quarter share count and implications of the IPO-related conversion and reverse split.